Guide for National Boards on endorsement for scheduled medicines released

06 Feb 2018

The Australian Health Practitioner Regulation Agency (AHPRA) has released a guide for National Boards on endorsement for scheduled medicines.

In 2016 the Ministerial Council endorsed the Australian Health Ministers’ Advisory Council’s Guidance for National Boards: Applications to the Ministerial Council for approval of endorsements in relation to scheduled medicines under section 14 of the National Law (the AHMAC Guidance).

The AHMAC Guidance endorsed by the Ministerial Council is available on the AHPRA website.

To support the implementation of the Guidance, AHPRA is publishing a supporting Guide for National Boards. The AHPRA Guide supports National Boards when developing a submission to the Ministerial Council seeking approval of a new or amended endorsement in relation to scheduled medicines under section 14 of the Health Practitioner Regulation National Law, as in force in each state and territory (the National Law).

The AHPRA Guide may also assist National Boards’ stakeholders in understanding the complexity and rigor of the process of developing a proposal for endorsement for scheduled medicines for a profession, from concept development to Ministerial Council approval. Stakeholders may use the AHPRA Guide for developing a concept to introduce an endorsement for a health profession or amend an existing one, including:

  • the stakeholder engagement that needs to be carried out
  • the key considerations for concept development, and
  • the suggested activities that may be completed during concept development.

The AHPRA Guide is now available together with the AHMAC Guidance on the Endorsement for scheduled medicines section of the AHPRA website.

 
 
Page reviewed 6/02/2018